Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Dec 30;24(2):157–166. doi: 10.1007/s10157-019-01810-w

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — Annualized rate of change in the glomerular filtration rate (mL/min/1.73 m²). a Annualized rate of change of eGFR_CKD-EPI from baseline to month 18. Dots are individual patient data. b Annualized rate of change of eGFR_CKD-EPI from baseline to month 48 in the 5 Japanese patients randomly assigned to the migalastat group at study entry. Because 1 patient was withdrawn from the study by the investigator at month 30 or thereafter, data for month 42 and month 48 are from the remaining 4 patients. Blue line is mean change from baseline; remaining lines represent individual patient data. c Annualized rate of change of mGFR_iohexol from baseline to month 18. eGFR_CKD-EPI estimated glomerular filtration rate calculated by the Chronic Kidney Disease Epidemiology Collaboration equation, ERT enzyme replacement therapy, mGFR_iohexol estimated glomerular filtration rate determined from clearance of iohexol, N/A not applicable, SD standard deviation

Fig. 2 — Annualized rate of change in the glomerular filtration rate (mL/min/1.73 m²). a Annualized rate of change of eGFR_CKD-EPI from baseline to month 18. Dots are individual patient data. b Annualized rate of change of eGFR_CKD-EPI from baseline to month 48 in the 5 Japanese patients randomly assigned to the migalastat group at study entry. Because 1 patient was withdrawn from the study by the investigator at month 30 or thereafter, data for month 42 and month 48 are from the remaining 4 patients. Blue line is mean change from baseline; remaining lines represent individual patient data. c Annualized rate of change of mGFR_iohexol from baseline to month 18. eGFR_CKD-EPI estimated glomerular filtration rate calculated by the Chronic Kidney Disease Epidemiology Collaboration equation, ERT enzyme replacement therapy, mGFR_iohexol estimated glomerular filtration rate determined from clearance of iohexol, N/A not applicable, SD standard deviation